A New Special Report Has Just Been Posted

Profiting off Pfizer’s Debacle

By Bryan Bottarelli
Monday, December 11, 2006 1:38 PM EST
Mon, 11 Dec 2006 18:38:00 GMT

“Pfizer’s failure is considered a win for Isis’s pipeline cholesterol drug. And Pfizer’s need for a next-generation cholesterol fighter is fanning speculation that it will buy Isis.”

- Barron’s, December 11th 2006

Dear Bottarelli Research Member,

On December 4th, shares of Pfizer (PFE – NYSE) went from $27.86 down to $23.50 on the news that the world’s largest drug-maker halted development of a key new cholesterol treatment. Based on this down-move, I got an idea for a new special report…

PFE

The purpose of this report is to isolate the one company that stands to benefit the most form Pfizer’s latest setback. And I’ve found the beneficiary in the form of a company called ISIS Pharmaceuticals (ISIS – NASDAQ). The purpose of this report is to show you how to make a small cash outlay to own longer-dated options on ISIS – and if the stock moves the way we want – you could easily have a 100% gainer on your hands!

ISIS

In terms of timing, right now is the ideal time to make plays like this. For one, Pfizer has opened the door for a smaller, sleeker competitor to swoop in and steal the billion-dollar market they just vacated. Secondly, Pfizer could also be looking to acquire a stock like ISIS to help them fill their massive void. Any takeover speculation – or takeover news – could send shares of ISIS soaring.

All my latest research is included in my new special report titled “Profiting off Pfizer’s Debacle.”

The recommendation you’re about to receive is designed to be held over the longer-term. I plan to manage the position by including any pertinent updates within your daily trading alerts. Unlike other newsletter services, which charge hundreds of extra dollars for this type of research, I will be giving this report to you free of charge.

The way I see it, it’s already included in the total benefit package of being a Charter Member to BottarelliResearch. So please, consider it an early Christmas present – and thank you for continuing your elite membership in our trading group.

To access your special report, simply log onto the Member’s Only section of the website and click on the report titled “Profiting off Pfizer’s Debacle” on the right-hand side of the page. There you will find the following recommendation – alongside a full write-up on the incredible opportunity that’s just opened up.

PLAY: Buy the ISIS January 2008 10 Calls (LFE AB) at or under $5.00. Current bid/ask spread is $4.50 to $4.70.

Log in right now to access your full write-up. And as always…

Lock and load!

Sincerely,

Bryan Bottarelli

Bryan Bottarelli
Editor, Bottarelli Research

© 2012 CSR Group, LLC. All rights reserved. Published in USA.

Information, opinion, research, and commentary contained herein is obtained from sources believed to be reliable; their reliability, however, cannot be guaranteed. The maxim of Caveat Emptor applies — let the buyer beware. Bottarelli Research does not provide individual investment advice, act as an investment advisor, or individually advocate the purchase or sale of any security or investment.

Investments recommended in this service should be made only after consulting with your investment advisor, and only after reviewing the prospectus or financial statements of the company. Bottarelli Research reserves the right to use e-mail endorsements and/or profit claims from its subscribers for marketing purposes. All names will be kept anonymous and only subscriber’s initials will be used unless express written permission has been granted to the contrary.

CSR Group, LLC expressly forbids its writers from having a financial interest in any security recommended to readers. Furthermore, all employees and agents of CSR Group, LLC and its affiliate companies must wait 24 hours before following a published recommendation.

Bottarelli Research alerts contain time-sensitive information, and are published and distributed to members with urgency. Because of this, not all published materials can be adequately proofread, and an occasional spelling or grammar error may exist.


Other Options Alerts From December 2006